Article Text

Download PDFPDF
Systematic review and meta-analysis
Meta-analysis finds benefit for dual antiplatelet therapy but limitations preclude changing standard mono antiplatelet therapy approach for acute non-cardioembolic ischaemic stroke or transient ischaemic attack
  1. Wilbert S Aronow
  1. Division of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, New York, USA
  1. Correspondence to : Dr Wilbert S Aronow, Division of Cardiology, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595, USA; wsaronow{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


Current guidelines recommend aspirin, aspirin plus clopidogrel or aspirin plus extended-release dipyridamole for treatment of acute ischaemic stroke (IS) or transient ischaemic attack (TIA) to prevent recurrent stroke, myocardial infarction and cardiovascular death.1 The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial randomised 5170 Chinese patients within 24 h after the onset of IS or TIA to clopidogrel plus aspirin versus aspirin plus placebo for 90 days. Clopidogrel plus …

View Full Text


  • Competing interests None.